Literature DB >> 1872670

Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim.

J Valeriano-Marcet1, H Spiera.   

Abstract

Sulfamethoxazole-trimethoprim may be an alternative or adjunctive treatment for Wegener's granulomatosis, as suggested by our experience with six patients. Two had limited Wegener's granulomatosis; one of these achieved remission with sulfamethoxazole-trimethoprim alone, and the second achieved remission with sulfamethoxazole-trimethoprim and prednisone. Four patients presented with sinus, pulmonary, and renal involvement. One patient initially treated with sulfamethoxazole-trimethoprim developed worsening renal function requiring cytotoxic therapy. Two patients initially treated with cytotoxic agents achieved remission coincident with the addition of sulfamethoxazole-trimethoprim for persistent sinus symptoms. One patient had relapse of pulmonary symptoms after achieving and maintaining a remission during treatment with sulfamethoxazole-trimethoprim alone. This experience suggests that sulfamethoxazole-trimethoprim may be an effective treatment for some patients with Wegener's granulomatosis and may be the only agent required. Patients require careful follow-up and still may need cytotoxic therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872670

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

Review 1.  An unusual case of multiple cranial nerve palsies in Wegener's granulomatosis.

Authors:  A D Daderian; S Chayasirisobhon
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

Review 2.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 3.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.